Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 févr. 2026 08h00 HE | Source: Abinopharm, Inc.

Abinopharm, Inc. Releases AbinoNutra® NMN White Paper Following FDA Reinstatement and Human Clinical Trial Evidence

SHELTON, Conn., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Abinopharm, Inc., a U.S.-based life-science company headquartered in Shelton, Connecticut, today announced the publication of its newly released...
06 juil. 2025 20h05 HE | Source: Abinopharm, Inc.

Abinopharm, Inc. and EGT Synbio Announce Successful Human Clinical Trials on Oral L-Ergothioneine (Dr.Ergo®) for Skin Health

Human Clinical Trial of L-Ergothioneine (Dr.Ergo®) on Skin Health
24 mars 2025 15h35 HE | Source: Abinopharm, Inc.

Abinopharm, Inc. warmly congratulates partner company EGT Synbio on receiving no objection letter from the FDA for their GRAS notification of Dr.Ergo®Ergothioneine

Abinopharm, Inc. and our partner, EGT Synbio, announced our Ergothioneine ingredient received GRAS status from FDA, the 2nd GRAS for Ergothioneine in US.